Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

Science

Volumn 283, Issue 5403, 1999, Pages 857-860

  Schmitz, Jörn E ^a   Kuroda, Marcelo J ^a   Santra, Sampa ^a   Sasseville, Vito G ^a,g   Simon, Meredith A ^a   Lifton, Michelle A ^a   Racz, Paul ^b   Tenner Racz, Klara ^b   Dalesandro, Margaret ^c,h   Scallon, Bernhard J ^c   Ghrayeb, John ^c   Forman, Meryl A ^d   Montefiori, David C ^e   Peter Rieber, E ^f   Letvin, Norman L ^a   Reimann, Keith A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c CENTOCOR INC   (United States)

^d M/C 195 10   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g BRISTOL MYERS SQUIBB   (United States)

^h Cambridge Pharma Consultancy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFECTION CONTROL; LYMPHOCYTE COUNT; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; GENE PRODUCTS, GAG; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MACACA MULATTA; NEUTRALIZATION TESTS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0033524838     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5403.857     Document Type: Article

References (25)

1. C. M. Walker, D. J. Moody, D. P. Stites, J. A. Levy, Science 234, 1563 (1986).
2. R. A. Koup et al., J. Virol. 68, 4650 (1994); P. Borrow, H. Lewicki, B. H. Hahn, G. M. Shaw, M. B. A. Oldstone, ibid., p. 6103.
3. R. A. Koup et al., J. Virol. 68, 4650 (1994); P. Borrow, H. Lewicki, B. H. Hahn, G. M. Shaw, M. B. A. Oldstone, ibid., p. 6103.
4. C. Rinaldo et al., ibid. 69, 5838 (1995); L. Musey et al., N. Engl. J. Med. 337, 1267 (1997); G. S. Ogg et al., Science 279, 2103 (1998).
5. C. Rinaldo et al., ibid. 69, 5838 (1995); L. Musey et al., N. Engl. J. Med. 337, 1267 (1997); G. S. Ogg et al., Science 279, 2103 (1998).
6. C. Rinaldo et al., ibid. 69, 5838 (1995); L. Musey et al., N. Engl. J. Med. 337, 1267 (1997); G. S. Ogg et al., Science 279, 2103 (1998).
7. N. L. Letvin and R. C. Desrosiers, Eds., Current Topics in Microbiology and Immunology, vol. 188, Simian Immunodeficiency Virus (Springer-Verlag, Berlin, 1994).
8. B. A. Castro et al., Clin. Immunol. Immunopathol. 65, 227 (1992); T. Matano et al., J. Virol. 72, 164 (1998).
9. B. A. Castro et al., Clin. Immunol. Immunopathol. 65, 227 (1992); T. Matano et al., J. Virol. 72, 164 (1998).
10. J. E. Schmitz et al., in preparation.
11. K. A. Reimann et al., J. Virol. 68, 2362 (1994).
12. A. N. Phillips, Science 271, 497 (1996).
13. + lymphocyte depletion during peak SIVmac viremia. In the chronic infection experiment monkeys were administered monoclonal antibodies >9 months after mucosal infection with SIVmac strain 251. All animals were maintained in accordance with the guidelines of the Committee on Animals for the Harvard Medical School and the Guide for the Care and Use of Laboratory Animals (National Research Council, National Academic Press, Washington, DC, 1996).
14. + lymphocyte depletion.
15. D. M. Neville Jr. et al., J. Immunother. Emphasis Tumor Immunol. 19, 85 (1996).
16. + lymphocyte depletion), statistical analyses between these groups defined by outcome were not performed because these groups were not defined prospectively.
17. M. J. Kuroda et al., J. Exp. Med. 187, 1373 (1998); A. Seth et al., Proc. Natl. Acad. Sci. U.S.A. 95, 10112 (1998).
18. M. J. Kuroda et al., J. Exp. Med. 187, 1373 (1998); A. Seth et al., Proc. Natl. Acad. Sci. U.S.A. 95, 10112 (1998).
19. M. J. Kuroda et al., in preparation.
20. L. Chakrabarti, M.-C. Cumont, L. Montagnier, B. Hurrel, J. Virol. 68, 6634 (1994); A. Watson et al., ibid. 71, 284 (1997).
21. L. Chakrabarti, M.-C. Cumont, L. Montagnier, B. Hurrel, J. Virol. 68, 5634 (1994); A. Watson et al., ibid. 71, 284 (1997).
22. D. C. Montefiori, data not shown. Neutralizing antibody titers were determined with a highly neutralization-sensitive, cell line-passaged SIVmac 251 isolate as described by A. J. Langlois et al. [J. Virol. 72, 6950 (1998)].
23. + lymphocyte repopulation.
24. K. Tenner-Racz et al., J. Exp. Med. 187, 949 (1998).
25. This work was supported by Department of Health and Human Services Public Health Service grants RR-13150 and RR-00168 and by the German Ministry of Education and Research (BMBF 01 K1-97146) (P.R. and K.T-R) and German Ministry of Education and Research AIDS Program (J.E.S.), Bonn, Germany. We are grateful for the assistance of K. H. Manson, P. K. Sehgal, D. Lee-Parritz, B. Raschdorff, G. Großchupff, R. A. Parker, and the Beth Israel Deaconess Medical Center Biometrics Center in performing these studies. We thank D. M. Neville Jr. for the gift of FN18.